MET, also known as the hepatocyte growth factor receptor (HGFR), is a protein that is involved in cellular growth, survival, and migration. In some cancers, the MET gene may become altered or amplified, leading to increased MET signaling and contributing to tumor growth and progression. Several targeted therapies have been developed or are under investigation for the treatment of MET-positive…
There have been several targeted therapies under development for the treatment of cancers with KRAS mutations. Sotorasib[1] One of the most promising targeted therapies for KRAS-mutant cancers is sotorasib (also known as AMG 510). Sotorasib specifically targets the KRAS G12C mutation, which is found in a subset of non-small cell…
ALK-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterized by the presence of an abnormal ALK gene fusion. Targeted therapies have been developed to specifically inhibit the activity of the ALK protein, which can help to control tumor growth and progression. The use of tyrosine kinase inhibitors (TKIs) has led to significantly…
BRAF V600 mutation-positive advanced non-small cell lung cancer (NSCLC) can be treated with targeted therapies that specifically inhibit the BRAF V600 mutation. These include: Dabrafenib[1] Dabrafenib is a selective inhibitor of the BRAF kinase that has been shown to be effective in treating NSCLC patients with the BRAF V600E mutation. It works by blocking the activity…
2 targeted drugs for treatment of the KRAS mutations cancer2 fármacos dirigidos para el tratamiento del cáncer con muta…
BIGBEAR Pharmaceutical announces the approval of Adagrasib i…
BIGBEAR Pharmaceutical announces the approval of Larotrectin…
Laos BIGBEAR Pharma’s Advanced JAK Inhibitor Pipeline:…
Copyright © 2021-2022 LienTeh.net All rights reserved.
